AbbVie Inc. (ABBV)
Should Investors Be Worried About Dividend King AbbVie?
Nearly everything looked great with AbbVie's (ABBV 3.10%) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq.
Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its oncology, neuroscience, and immunology franchises. So, total sales of Rinvoq and Skyrizi reached $5.14 billion in the first three months of 2025, increasing by 65.8% year-on-year.
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
Why AbbVie Stock Topped the Market Today
A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (ABBV 3.10%) stock an investor darling on Friday. The pharmaceutical company's performance pushed its stock to a more than 3% gain on the day, well higher than the 0.6% bump of the bellwether S&P 500 index it's a part of.
AbbVie's First Quarter Beat And Raise Leaves Room For More
AbbVie Inc. beat first-quarter revenue and EPS estimates and raised the full-year EPS guidance by $0.10 and revenue guidance by $700 million. Skyrizi and Rinvoq drove the ABBV Q1 beat with exceptional growth, leading to increased full-year revenue net sales guidance for both drugs. The immunology and neuroscience segments showed robust performance, supporting a bullish outlook, while Humira, the aesthetics, and eye care segments remain weak spots.
AbbVie: Q1 Earnings Reinforce Positive Momentum
AbbVie Inc.'s Q1 2025 results exceeded expectations on the earnings front, but the key question is whether the stock is an immediate buy. It saw an accelerated 8.4% YoY revenue growth, driven by strong performance from immunology. Earnings also surprised positively, leading to an upgrade in full-year guidance. Despite this, though, the forward non-GAAP P/E ratio at 15x looks rich compared to both past averages and a comparison with peers.
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
AbbVie Stock Rises on Stronger-Than-Expected Results, Profit Outlook Lift
AbbVie (ABBV) on Friday reported first-quarter results that came in above analysts' estimates, and lifted its full-year profit guidance.
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2 Pharma Stocks Buzzing in the Options Pits After Earnings
Pharmaceutical stocks are making headlines today, after two U.S.-based sector heavyweights stepped into the earnings confessional this morning and last night.
AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates
AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.31 per share a year ago.
AbbVie lifts guidance as Q1 results top expectations
Abbvie Inc (NYSE:ABBV) shares moved higher after it reported strong results for the first quarter of 2025 and raised its full-year profit guidance. The company now expects adjusted earnings per share (EPS) in the range of $12.09 to $12.29, up from its earlier guidance of $11.99 to $12.19.
